Source facts
FDA issued a tentative approval letter for ANDA 220169 on 2026-06-08. The source metadata identifies ANDA 220169 as an original application. Review the exact FDA letter for the approved conditions and labeling.
US FDA source recordTA · Tentative Approval Letter
ANDA 220169 — FDA Tentative Approval Letter
Issued to APOTEX INC. Application meets requirements but marketing is blocked (patent/exclusivity).
Issued
June 8, 2026Application
ANDA 505j • 220169
Product
ANDA 220169
Company
APOTEX INC
Stage
Final Decision
Assyro regulatory brief
FreeWhat did FDA decide for ANDA 220169?
Source facts and Assyro context are separated so you can scan the action quickly without treating analysis as an FDA conclusion.
Key details in this letter
- 1FDA action: tentative approval.
- 2Application: ANDA 220169.
- 3Submission: original application.
- 4Sponsor: APOTEX INC.
Suggested next step
Review the exact FDA letter for approved conditions, labeling, and postmarketing requirements.
Open the document workspaceFDA source document
Read the full FDA tentative approval letter (PDF)
Loading document viewer…
Common questions about the ANDA 220169 tentative approval letter
Is ANDA 220169 FDA approved?
Not for marketing yet. FDA granted tentative approval to ANDA 220169 for ANDA 220169 on June 8, 2026, meaning the application meets approval standards but patent or exclusivity protections block final approval. The product cannot be marketed until those conditions resolve and FDA issues final approval.
What is ANDA 220169?
ANDA 220169 is the application under which FDA issued this tentative approval letter to APOTEX INC. The letter is dated June 8, 2026.
What happens after an FDA tentative approval letter?
The product cannot be marketed yet. Tentative approval means the application meets FDA approval standards, but patent or exclusivity protections block final approval. The sponsor typically requests final approval as the blocking date approaches, and FDA re-verifies that the approval conditions still hold before granting it.